Venetia, Pennsylvania, United States
I build high-performing teams and execution capabilities that make programs deliver — and ensures that capability transfers and sustains across the organization long after a program closes. With 20+ years of experience across regulated product development, I've operated at the intersection of direct program leadership and portfolio oversight — running high-stakes programs myself while simultaneously building the frameworks that keep complex portfolios on track. I've done both by design, because the best governance comes from leaders who understand what delivery actually feels like from inside a program. Programs I've led range from enterprise risk mitigation protecting $300M+ in annual revenue, to global supply chain buildouts, to launch excellence frameworks for a EUR 750M device portfolio. The common thread is taking complex, cross-functional challenges with real business stakes and driving them to a defined outcome — on time, within investment, and with the organizational approach and methodology to sustain results after I'm done. My methodology is portable. I've applied the same operational and financial discipline that I built across regulated product development environments to a growing healthcare practice — delivering measurable improvements in revenue performance, patient growth, and operational efficiency. The methods travel — what changes is the domain context. I'm selectively exploring director-level program and portfolio leadership roles, and/or contract engagements where an organization needs embedded execution capability on a high-stakes initiative. Industries I'm open to include medical device, aerospace, defense, industrial manufacturing, healthcare IT, and any operationally complex environment where governance and delivery discipline are valued. Pittsburgh-based. Open to remote and travel.
Family-owned pediatric dental practice — engaged in back-office operations, financial management, and insurance strategy. Increased direct involvement in 2024 to address profitability, patient growth, and operational infrastructure gaps. - Drove +15% patient base growth and +10% procedure volume growth (2024–2025) through insurance carrier realignment, new patient intake redesign, and scheduling optimization - Improved insurance reimbursement rate +5% through carrier renegotiations, fee schedule optimization, and strategic network structure - Reduced accounts receivable over 90 days by 50% through custom reporting infrastructure, upfront payment protocols, and structured follow-up process
Division-level initiative defining and building the launch excellence framework for a EUR 750M global medical device and service portfolio. Delivered a formal launch excellence framework — resolving organizational misalignment on launch definition via, - Drove alignment across 25+ senior stakeholders on launch accountability scope, backed by benchmark analysis and post-launch assessment to business case to demonstrate product distribution was not the primary investment efficiency problem relative to product launch. - Established KPI framework, risk retirement methodology, and self-sustaining continuous improvement capability transferred to functional representatives for implementation
Dual role by design — retained active program leadership concurrent with PMO responsibilities to maintain execution credibility and organizational connectivity. ISO Process Owner for Product Realization / Design Controls, including serving as primary organizational representative for design control elements in internal and external audits. - Unified global QMS across six legacy frameworks into a single ISO 13485:2016 and FDA 820-compliant structure; leading organization-wide training for 400+ FTE across global sites - Designed six-stage governance model enabling executive portfolio oversight across $150M annual investment; serving as official minutes owner for all stage gate reviews - Eliminated $120M annual margin exposure through enterprise supply chain risk program protecting $300M+ revenue; securing 5-year supply commitment without disruption
Led cross-functional teams from customer need assessment through global commercialization across combination products, electro-mechanical systems, SaMD, and high-volume medical device consumables. Teams 12–40 FTE, budgets $8–20M, durations 3–5 years - Established European manufacturing capability for a new combination product syringe line across three countries — delivered on time within $15M capital investment - Revitalized flagship radiology product line via healthcare informatics integration — delivering software applications, updated UI, and 10% hardware cost reduction
Led cross-functional teams from customer need assessment through global commercialization across combination products, electro-mechanical systems, SaMD, and high-volume medical device consumables. Teams 12–40 FTE, budgets $8–20M, durations 3–5 years.